ES2675102T3 - Método de radioconjugación - Google Patents

Método de radioconjugación Download PDF

Info

Publication number
ES2675102T3
ES2675102T3 ES11788862.8T ES11788862T ES2675102T3 ES 2675102 T3 ES2675102 T3 ES 2675102T3 ES 11788862 T ES11788862 T ES 11788862T ES 2675102 T3 ES2675102 T3 ES 2675102T3
Authority
ES
Spain
Prior art keywords
peptide
formula
compound
btm
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11788862.8T
Other languages
English (en)
Spanish (es)
Inventor
Bard Indrevoll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare UK Ltd
Original Assignee
GE Healthcare UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1020314.9A external-priority patent/GB201020314D0/en
Priority claimed from GBGB1106593.5A external-priority patent/GB201106593D0/en
Application filed by GE Healthcare UK Ltd filed Critical GE Healthcare UK Ltd
Application granted granted Critical
Publication of ES2675102T3 publication Critical patent/ES2675102T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/02—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES11788862.8T 2010-12-01 2011-12-01 Método de radioconjugación Active ES2675102T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1020314.9A GB201020314D0 (en) 2010-12-01 2010-12-01 Apoptosis pet imaging agents
GB201020314 2010-12-01
US201161476805P 2011-04-19 2011-04-19
US201161476805P 2011-04-19
GB201106593 2011-04-19
GBGB1106593.5A GB201106593D0 (en) 2011-04-19 2011-04-19 Radioconjugation method
PCT/EP2011/071506 WO2012072736A2 (en) 2010-12-01 2011-12-01 Radioconjugation method

Publications (1)

Publication Number Publication Date
ES2675102T3 true ES2675102T3 (es) 2018-07-06

Family

ID=45063153

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11788862.8T Active ES2675102T3 (es) 2010-12-01 2011-12-01 Método de radioconjugación
ES18167523T Active ES2929507T3 (es) 2010-12-01 2011-12-01 Método para marcar una molécula directora biológica mediante conjugación con un radioisótopo adecuado para formación de imágenes por PET o SPECT

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18167523T Active ES2929507T3 (es) 2010-12-01 2011-12-01 Método para marcar una molécula directora biológica mediante conjugación con un radioisótopo adecuado para formación de imágenes por PET o SPECT

Country Status (12)

Country Link
US (2) US9493504B2 (enExample)
EP (2) EP3395373B1 (enExample)
JP (1) JP6231882B2 (enExample)
KR (1) KR20130119957A (enExample)
CN (2) CN103269725B (enExample)
AU (1) AU2011334881A1 (enExample)
BR (1) BR112013013283A2 (enExample)
CA (1) CA2819347A1 (enExample)
ES (2) ES2675102T3 (enExample)
MX (1) MX2013006202A (enExample)
RU (1) RU2013122649A (enExample)
WO (1) WO2012072736A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2819347A1 (en) * 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method
GB201314936D0 (en) * 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
GB201322451D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
BR112020010436A2 (pt) * 2018-01-26 2020-11-24 F. Hoffmann-La Roche Ag oligonucleotídeo radiomarcado, processos para a preparação de um oligonucleotídeo radiomarcado, uso do oligonucleotídeo radiomarcado, método para determinar a biodistribuição e farmacocinética e oligonucleotídeo

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040662A2 (en) * 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
CA2556169C (en) * 2004-01-29 2011-11-22 Andrew Lees Use of amino-oxy functional groups in the preparation of vaccines
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
GB0420365D0 (en) 2004-09-14 2004-10-13 Hammersmith Imanet Ltd Radiolabelled insulin
US8241606B2 (en) 2006-12-18 2012-08-14 Ge Healthcare As Synthesis of a radiofluorinated peptide using photolabile protecting groups
US8216548B2 (en) * 2006-12-28 2012-07-10 Ge Healthcare As Radiofluorination methods
US8545809B2 (en) * 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
US20080274046A1 (en) * 2007-02-20 2008-11-06 Christian Prenant Radiolabelling
GB0803477D0 (en) * 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
CA2819347A1 (en) * 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method

Also Published As

Publication number Publication date
CN104984372B (zh) 2018-11-09
CN103269725A (zh) 2013-08-28
US20170044080A1 (en) 2017-02-16
ES2929507T3 (es) 2022-11-29
JP2014500883A (ja) 2014-01-16
WO2012072736A3 (en) 2012-10-18
CN103269725B (zh) 2015-09-23
AU2011334881A1 (en) 2013-06-06
EP2646060A2 (en) 2013-10-09
US20130259803A1 (en) 2013-10-03
US9493504B2 (en) 2016-11-15
EP3395373B1 (en) 2022-10-19
CN104984372A (zh) 2015-10-21
RU2013122649A (ru) 2015-01-10
MX2013006202A (es) 2013-07-29
JP6231882B2 (ja) 2017-11-15
EP2646060B1 (en) 2018-05-30
KR20130119957A (ko) 2013-11-01
EP3395373A1 (en) 2018-10-31
WO2012072736A2 (en) 2012-06-07
CA2819347A1 (en) 2012-06-07
BR112013013283A2 (pt) 2016-11-22

Similar Documents

Publication Publication Date Title
CA2807491C (en) F18 c-met binding cyclic peptide radiotracers and compositions thereof
US20220202965A1 (en) Radiotracer compositions and methods
US20210330824A1 (en) Purification method and compositions
ES2929507T3 (es) Método para marcar una molécula directora biológica mediante conjugación con un radioisótopo adecuado para formación de imágenes por PET o SPECT
ES2764119T3 (es) Método de radiomarcaje
HK1226050A1 (en) Purification method and compositions